Trial · NCT03568175
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid | Baseline to 52 weeks | |
| Secondary | Change From Baseline in Serum Heparan Sulfate Levels. | Baseline, 24-26 weeks, 50-52 weeks | |
| Secondary | Change From Baseline in Serum Dermatan Sulfate Levels. | Baseline, 24-26 weeks, 50-52 weeks | |
| Secondary | Change From Baseline in Urinary Heparan Sulfate Levels. | Baseline, 25 weeks, 52 weeks | |
| Secondary | Change From Baseline in Urinary Dermatan Sulfate Levels. | Baseline, 25 weeks, 52 weeks | |
| Secondary | Change From Baseline in Liver Volumes. | Baseline, 25 weeks, 52 weeks | |
| Secondary | Change From Baseline in Spleen Volumes. | Baseline, 25 weeks, 52 weeks | |
| Secondary | Change From Baseline in Cardiac Function. | Baseline, 25 weeks, 52 weeks | |
| Secondary | Change From Baseline in 6-minute Walk Test Distance. | Baseline, 25 weeks, 52 weeks | Item 9 will be administrated only in patients judged by the investigator or subinvestigator to be possible to perform the 6-minutes walk test |
| Secondary | Change From Baseline in Joint Range of Motion. | Baseline, 25 weeks, 52 weeks | |
| Secondary | Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid. | Baseline to 25 weeks | |
| Secondary | Change From Baseline in Dermatan Sulfate Levels in Cerebrospinal Fluid. | Baseline, 25 weeks, 52 weeks | |
| Secondary | Change from Baseline in Neurocognitive Testing (Kyoto Scale of Psychological Development 2001) | 25, 52 weeks | |
| Secondary | Change from Baseline in Adaptive Behavioral Testing ( Vineland Adaptive Behavior Scales Second Edition. ) | 25, 52 weeks | |
| Secondary | Drug concentration in Cerebrospinal Fluid. | 25, 52*weeks | \*Drug concentration in Cerebrospinal Fluid at 52 Weeks is applicable only for subjects to be enrolled in extension study . |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03568175/registered